TMVr is a minimally invasive technique for treatment of significant, symptomatic, degenerative mitral regurgitation (MR). It is performed using venous access and real-time imaging, thereby avoiding cardiopulmonary bypass. Patients generally recover within the post-procedure hospitalization and demonstrate improved functional capacity and quality of life.1

This treatment increases the options for patients who are at prohibitive risk for surgical intervention.

Transcatheter Mitral Valve Repair (TMVr) with MitraClip™ Therapy



MR is a condition in which the heart's mitral valve leaflets do not close tightly. When this happens, blood flows backward from the heart's left ventricle into the left atrium. The heart must then work harder to push blood through the body, which can cause fatigue, shortness of breath, and worsening heart failure.2

MR is the most frequent valve disease in the United States.3,4 Over 4 million people have significant MR, with an annual incidence of 250,000.3-5


For symptomatic patients diagnosed with moderate-severe or severe degenerative MR, surgery is generally recommended to repair or replace the mitral valve. This typically involves open-heart surgery with the patient on cardiopulmonary bypass.1,6

According to the 2017 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease, transcatheter mitral valve repair (TMVr) with MitraClip therapy may be considered for patients with clinically significant degenerative MR who are not suitable for surgery.6


The world's first transcatheter mitral valve repair (TMVr) system delivers a therapeutic option for select high-surgical-risk patients with degenerative MR who would otherwise go untreated.7



1. Sorajja P, et al. Initial experience with commercial transcatheter mitral valve repair in the United States. J Am Coll Cardiol. 2016;67(10):1129-1140.
2. MedLine Plus Medical Encyclopedia. Mitral valve regurgitation. Accessed July 24, 2018.
3. Benjamin EJ, et al. Heart Disease and Stroke Statistics—2018 Update. A Report From the American Heart Association. Circulation. 2018;137:e67–e492. DOI: 10.1161/CIR.0000000000000558
4. Nkomo VT, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005-1011.
5. US Census Bureau. 2012-2016 American Community Survey Census Bureau 5-Year Estimates.
6. Nishimura RA, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135(25):e1159-e1195.
7. MitraClip NTR XTR Clip Delivery System Instructions for Use.





The MitraClip® System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus [degenerative MR] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.


The MitraClip® System is contraindicated in DMR patients with the following conditions:

  • Patients who cannot tolerate procedural anticoagulation or post procedural antiplatelet regimen
  • Active endocarditis of the mitral valve
  • Rheumatic mitral valve disease
  • Evidence of intracardiac, inferior vena cava (IVC) or femoral
    venous thrombus


  • DO NOT use MitraClip® outside of the labeled indication. Treatment of non-prohibitive risk DMR patients should be conducted in accordance with standard hospital practices for surgical repair and replacement.
  • MitraClip® is intended to reduce mitral regurgitation. The MitraClip® procedure is recommended to be performed when an experienced heart team has determined that reduction of MR to ≤ 2+ is reasonably expected following the MitraClip®. If MR reduction to ≤ 2+ is not achieved, the benefits of reduced symptoms and hospitalizations, improved quality of life, and reverse LV remodeling expected from MitraClip® may not occur.
  • The MitraClip® Implant should be implanted with sterile techniques using fluoroscopy and echocardiography (e.g., transesophageal [TEE] and transthoracic [TTE]) in a facility with on-site cardiac surgery and immediate access to a cardiac operating room.
  • Read all instructions carefully. Failure to follow these instructions, warnings and precautions may lead to device damage, user injury or patient injury. Use universal precautions for biohazards and sharps while handling the MitraClip® System to avoid user injury.
  • Use of the MitraClip® should be restricted to those physicians trained to perform invasive endovascular and transseptal procedures and those trained in the proper use of the system.
  • The Clip Delivery System is provided sterile and designed for single use only. Cleaning, re-sterilization and / or reuse may result in infections, malfunction of the device or other serious injury or death.


Patient Selection:
    • Prohibitive risk is determined by the clinical judgment of a heart team, including a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, due to the presence of one or more of the following documented surgical risk factors:
      • 30-day STS predicted operative mortality risk score of
        • ≥8% for patients deemed likely to undergo mitral valve replacement or
        • ≥6% for patients deemed likely to undergo mitral valve repair
      • Porcelain aorta or extensively calcified ascending aorta.
      • Frailty (assessed by in-person cardiac surgeon consultation)
      • Hostile chest
      • Severe liver disease / cirrhosis (MELD Score > 12)
      • Severe pulmonary hypertension (systolic pulmonary artery pressure > 2/3 systemic pressure)
      • Unusual extenuating circumstance, such as right ventricular dysfunction with severe tricuspid regurgitation, chemotherapy for malignancy, major bleeding diathesis, immobility, AIDS, severe dementia, high risk of aspiration, internal mammary artery (IMA) at high risk of injury, etc.
    • Evaluable data regarding safety or effectiveness is not available for prohibitive risk DMR patients with an LVEF < 20% or an LVESD > 60 mm. MitraClip® should be used only when criteria for clip suitability for DMR have been met.
  • The major clinical benefits of the MitraClip® Implant are a reduction of MR to ≤ 2+ resulting in reduced hospitalizations, improved quality of life, reverse LV remodeling and symptomatic relief in patients who have no other therapeutic option. No mortality benefit following MitraClip® therapy has been demonstrated.
  • The heart team should include a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease and may also include appropriate physicians to assess the adequacy of heart failure treatment and valvular anatomy.
  • The heart team may determine an in-person surgical consult is needed to complete the assessment of prohibitive risk. The experienced mitral valve surgeon and heart team should take into account the outcome of this surgical consult when making the final determination of patient risk status.
  • For reasonable assurance of device effectiveness, pre-procedural evaluation of the mitral valve and underlying pathologic anatomy and procedural echocardiographic assessment are essential.
  • Note the product “Use by” date specified on 
the package.
  • Inspect all product prior to use. Do not use if the package is open or damaged, or if product is damaged.


  • Mitral Valve Etiology
    Safety and effectiveness of the MitraClip® device has not been established in patients with MR due to underlying ventricular pathology (functional mitral regurgitation or FMR).
  • Pregnancy
    The MitraClip® device has not been tested in pregnant women. Effects on the developing fetus have not been studied. The risks and reproductive effects are unknown at this time.
  • Gender
    No safety or effectiveness related gender differences were observed in clinical studies.
  • Ethnicity
    Insufficient subject numbers prevent ethnicity-related analyses on the clinical safety and effectiveness.
  • Pediatrics
    Safety and effectiveness of the MitraClip® device has not been established in pediatric patients.
  • Anatomic Considerations
    For optimal results, the following anatomic patient characteristics should be considered. The safety and effectiveness of the MitraClip® outside of these conditions has not been established. Use outside these conditions may interfere with placement of the MitraClip® Implant or mitral valve leaflet insertion.
    • The primary regurgitant jet is non-commissural.
If a secondary jet exists, it must be considered clinically insignificant
    • Mitral valve area ≥ 4.0 cm2
    • Minimal calcification in the grasping area
    • No leaflet cleft in the grasping area
    • Flail width < 15 mm and flail gap < 10 mm


The following ANTICIPATED EVENTS have been identified as possible complications of the MitraClip® procedure.

Allergic reaction (anesthetic, contrast, Heparin, nickel alloy, latex); Aneurysm or pseudo-aneurysm; Arrhythmias; Atrial fibrillation; Atrial septal defect requiring intervention; Arterio-venous fistula; Bleeding; Cardiac arrest; Cardiac perforation; Cardiac tamponade / Pericardial Effusion; Chordal entanglement / rupture; Coagulopathy; Conversion to standard valve surgery; Death; Deep venous thrombus (DVT); Dislodgement of previously implanted devices; Dizziness; Drug reaction to anti-platelet / anticoagulation agents / contrast media; Dyskinesia; Dyspnea; Edema; Emboli (air, thrombus, MitraClip® Implant); Emergency cardiac surgery; Endocarditis; Esophageal irritation; Esophageal perforation or stricture; Failure to deliver MitraClip® to the intended site; Failure to retrieve MitraClip® System components; Fever or hyperthermia; Gastrointestinal bleeding or infarct; Hematoma; Hemolysis; Hemorrhage requiring transfusion; Hypotension / hypertension; Infection; Injury to mitral valve complicating or
preventing later surgical repair; Lymphatic complications; Mesenteric ischemia; MitraClip® Implanterosion, migration or malposition; MitraClip® Implant thrombosis; MitraClip® System component(s) embolization; Mitral stenosis; Mitral valve injury; Multi-system organ failure; Myocardial infarction; Nausea / vomiting; Pain; Peripheral ischemia; Prolonged angina; Prolonged ventilation; Pulmonary congestion; Pulmonary thrombo-embolism; Renal insufficiency or failure; Respiratory failure / atelectasis / pneumonia; Septicemia; Shock, Anaphylactic or Cardiogenic; Single leaflet device attachment (SLDA); Skin injury or tissue changes due to exposure to ionizing radiation; Stroke or transient ischemic attack (TIA); Urinary tract infection; Vascular trauma, dissection or occlusion; Vessel spasm; Vessel perforation or laceration; Worsening heart failure; Worsening mitral regurgitation; Wound dehiscence

AP2946592-WBU Rev. A



© 2019 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.